Maryland House Bill HB956

Maryland 2023 Regular Session

• Introduced: 2/10/23
• Refer: 2/10/23

Caption

Pregnant and Perinatal Drug Screening and Testing Workgroup

Impact

The workgroup will conduct a comprehensive analysis of existing drug screening practices and their effectiveness, as well as gather data on substance-exposed infants. By focusing on identifying and addressing substance use in pregnant individuals, the bill seeks to enhance medical practices and potentially improve outcomes for both mothers and their children. The inclusion of a racial equity impact assessment aims to ensure that the recommendations account for disparities in healthcare access and outcomes among various demographic groups, contributing to a more equitable approach in addressing these issues.

Summary

House Bill 956 establishes a Pregnant and Perinatal Drug Screening and Testing Workgroup within the Maryland Department of Health. The objective of this workgroup is to research and evaluate current practices and evidence-based methodologies related to drug screening and testing for pregnant individuals and newborns. This initiative underscores the growing concern regarding substance use disorders and their implications on maternal and infant health, aiming to develop informed guidelines for healthcare practices across the state.

Contention

While the bill has received support for its intention to safeguard the health of both mothers and newborns, potential contention may arise around the ethical considerations of drug screening and testing. Critics might argue about the implications of increased surveillance on pregnant individuals, particularly concerning privacy and informed consent. Discussions around the adequacy of resources to support families identified through these screenings may also surface, as well as the necessity for community support systems to address substance use disorders comprehensively.